MAPT and Alzheimer disease: Prior studies have shown that the AD genetic risk factor, BIN1, is involved in regulating RAB5-mediated endocytosis to modulate both Aβ and tau pathology in AD, by either “freeing” or “sequestering” the BIN1 binding partner and RAB5 effector, RIN317,39.